Stifel resumed coverage of Fulcrum Therapeutics (FULC) with a Buy rating and $20 price target Recent 12mg data already support a “compelling profile” for pociredir and the “bar” for the full 20mg cohort is low, argues the analyst, who adds that there’s “a blockbuster opportunity that supports meaningful upside” even as Fulcrum’s trial population and criteria exists today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics’ Earnings Call Highlights Progress and Potential
- Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler
- Fulcrum Therapeutics Reports Q3 2025 Progress and Financials
- Fulcrum Therapeutics reports Q3 EPS (31c), consensus (29c)
- Promising Preclinical Data and Strategic Expansion Drive Buy Rating for Fulcrum Therapeutics